Galecto Inc (GLTO) - Total Assets
Based on the latest financial reports, Galecto Inc (GLTO) holds total assets worth $10.74 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Galecto Inc net assets for net asset value and shareholders' equity analysis.
Galecto Inc - Total Assets Trend (2018–2024)
This chart illustrates how Galecto Inc's total assets have evolved over time, based on quarterly financial data.
Galecto Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Galecto Inc's total assets of $10.74 Million consist of 98.3% current assets and 1.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 82.7% |
| Accounts Receivable | $881.00K | 5.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Galecto Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see GLTO market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Galecto Inc's current assets represent 98.3% of total assets in 2024, a decrease from 99.6% in 2018.
- Cash Position: Cash and equivalents constituted 82.7% of total assets in 2024, down from 88.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 5.1% of total assets.
Galecto Inc Competitors by Total Assets
Key competitors of Galecto Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Galecto Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.73 | 8.68 | 30.42 |
| Quick Ratio | 3.73 | 9.17 | 29.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $7.16 Million | $18.74 Million | $163.73 Million |
Galecto Inc - Advanced Valuation Insights
This section examines the relationship between Galecto Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 259.18 |
| Latest Market Cap to Assets Ratio | 2.36 |
| Asset Growth Rate (YoY) | -55.2% |
| Total Assets | $17.13 Million |
| Market Capitalization | $40.39 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Galecto Inc's assets at a significant premium (2.36x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Galecto Inc's assets decreased by 55.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Galecto Inc (2018–2024)
The table below shows the annual total assets of Galecto Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $17.13 Million | -55.18% |
| 2023-12-31 | $38.23 Million | -47.77% |
| 2022-12-31 | $73.19 Million | -40.12% |
| 2021-12-31 | $122.22 Million | -28.78% |
| 2020-12-31 | $171.60 Million | +203.12% |
| 2019-12-31 | $56.61 Million | +61.26% |
| 2018-12-31 | $35.10 Million | -- |
About Galecto Inc
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, In… Read more